Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (Q57658712)

From Wikidata

Jump to navigation Jump to search

scholarly article by Dean Regier et al published April 2007 in Expert Review of Pharmacoeconomics & Outcomes Research

Language	Label	Description	Also known as
English	Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis	scholarly article by Dean Regier et al published April 2007 in Expert Review of Pharmacoeconomics & Outcomes Research

Statements

scholarly article

0 references

Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (English)

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

object named as

Dean A Regier

1

0 references

object named as

Nick Bansback

2

0 references

author name string

Anne Dar Santos

3

0 references

Carlo A Marra

4

0 references

publication date

April 2007

0 references

Expert Review of Pharmacoeconomics & Outcomes Research

0 references

7

0 references

2

0 references

155-169

0 references

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Rheumatoid arthritis and the risk of malignancy

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Psoriatic arthritis. Historical background and epidemiology

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

ARAMIS today: moving toward internationally distributed databank systems for follow-up studies.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Assessment of patients with psoriatic arthritis: a review of currently available measures

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Variation in the estimation of quality-adjusted life-years by different preference-based instruments.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

The British Society for Rheumatology biologics register

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Problems encountered during anti-tumour necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Epidemiology of ankylosing spondylitis in rochester, minnesota, 1935–1973

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Health economic evaluation: a primer for the practicing rheumatologist

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Costs of ankylosing spondylitis in three European countries: the patient's perspective.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Use of biologics in rheumatoid arthritis: where are we going?

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Epidemiology and burden of illness of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.155

21 January 2018

Identifiers

10.1586/14737167.7.2.155

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57658712&oldid=1546239762"